Chongqing McPhar New Pharmaceutical

Chongqing McPhar New Pharmaceutical is a clinical-stage biotechnology company headquartered in Chongqing, China, dedicated to the development of innovative small molecule drugs. The company's primary focus lies in metabolic disorders, particularly hyperuricemia and gout, where its lead candidate MP-001 acts as a potent URAT1 inhibitor. Beyond its lead program, McPhar is advancing a diverse pipeline of candidates targeting inflammatory and metabolic pathways. The firm integrates drug design, lead optimization, and clinical development to address significant unmet medical needs in the Chinese and global markets. Its research facilities are equipped for comprehensive chemical synthesis and biological evaluation. McPhar aims to provide high-quality, affordable innovative medicines through its proprietary R&D engine.